SEC Comment Letter for Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Apr 20, 2020
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: April 20, 2020 · CIK: 0000819050 · Accession: 0000000000-20-003384
AI Filing Summary & Sentiment
File numbers found in text: 333-237568
Letter
April 17, 2020 Robert Brown Chief Executive Officer Brickell Biotech, Inc. 5777 Central Avenue Suite 102 Boulder, CO 80301 Re:Brickell Biotech, Inc. Registration Statement on Form S-1 Filed April 3, 2020 File No. 333-237568 Dear Mr. Brown: We have limited our review of your registration statement to those issues we have addressed in our comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Registration Statement on Form S-1 General 1.Please revise the prospectus coverpage to identify Lincoln Park Capital Fund, LLC as an underwriter. For guidance, refer to Question 139.13 of the Securities Act Sections Compliance and Disclosure Interpretations. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameRobert Brown Comapany NameBrickell Biotech, Inc. April 17, 2020 Page 2 FirstName LastName Robert Brown Brickell Biotech, Inc. April 17, 2020 Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. You may contact Christopher Edwards at (202) 551-6761 or Joe McCann at (202) 551- 6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
April 17, 2020
Robert Brown
Chief Executive Officer
Brickell Biotech, Inc.
5777 Central Avenue
Suite 102
Boulder, CO 80301
Re:Brickell Biotech, Inc.
Registration Statement on Form S-1
Filed April 3, 2020
File No. 333-237568
Dear Mr. Brown:
We have limited our review of your registration statement to those issues we have
addressed in our comment. In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to the comment, we may have additional comments.
Registration Statement on Form S-1
General
1.Please revise the prospectus coverpage to identify Lincoln Park Capital Fund, LLC as an
underwriter. For guidance, refer to Question 139.13 of the Securities Act
Sections Compliance and Disclosure Interpretations.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameRobert Brown
Comapany NameBrickell Biotech, Inc.
April 17, 2020 Page 2
FirstName LastName
Robert Brown
Brickell Biotech, Inc.
April 17, 2020
Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
You may contact Christopher Edwards at (202) 551-6761 or Joe McCann at (202) 551-
6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences